Recent data suggest that Nadecenemab , a experimental drug, has the potential to reduce the progression of preclinical cognitive decline. This treatment targets removing beta-amyloid within the brain https://bookmark-dofollow.com/story28224015/nadecenemab-an-emerging-innovative-dementia-approach